Cargando…

The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico

ABSTRACT: Coronavirus diseases 2019 (COVID-19) are seriously affecting human health all over the world. Nucleotide inhibitors have promising results in terms of its efficacy against different viral polymerases. In this study, detailed molecular docking and dynamics simulations are used to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elfiky, Abdo A., Azzam, Eman B., Shafaa, Medhat W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778578/ https://www.ncbi.nlm.nih.gov/pubmed/33389441 http://dx.doi.org/10.1007/s11030-020-10178-z

Ejemplares similares

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
por: Elfiky, Abdo A.
Publicado: (2020)

Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]
por: Elfiky, Abdo A.
Publicado: (2020)

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
por: Elfiky, Abdo A.
Publicado: (2020)

Repurposing antiviral drugs against the human monkeypox virus DNA-dependent RNA polymerase; in silico perspective
por: Abduljalil, Jameel M., et al.
Publicado: (2022)

Exploration of natural compounds against the human mpox virus DNA-dependent RNA polymerase in silico
por: Abduljalil, Jameel M., et al.
Publicado: (2023)

Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective
por: Sonousi, Amr, et al.
Publicado: (2021)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
por: Kayali, Zeid, et al.
Publicado: (2014)

Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an in silico perspective
por: Ogunyemi, Oludare M, et al.
Publicado: (2020)

Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
por: Jockusch, Steffen, et al.
Publicado: (2020)

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
por: Tchesnokov, Egor P., et al.
Publicado: (2019)

Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
por: Buonaguro, Luigi, et al.
Publicado: (2020)

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs
por: Reynard, Olivier, et al.
Publicado: (2016)

Remdesivir/tocilizumab: Rebound of HCV viral load and loss of anti-HBs: case report
Publicado: (2021)

Development of an EBOV MiniG plus system as an advanced tool for anti-Ebola virus drug screening
por: Hsu, Chi-Ju, et al.
Publicado: (2023)

In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase
por: Celik, Ismail, et al.
Publicado: (2021)

Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase
por: Elfiky, Abdo A., et al.
Publicado: (2022)

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
por: Yin, Wanchao, et al.
Publicado: (2020)

Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2
por: Arba, Muhammad, et al.
Publicado: (2021)

Ebola virus (EBOV) infection: Therapeutic strategies
por: De Clercq, Erik
Publicado: (2015)

Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an in silico perspective
por: Elfiky, Abdo A
Publicado: (2022)

Identification of promising anti-EBOV inhibitors: de novo drug design, molecular docking and molecular dynamics studies
por: Mohamed, Eslam A. R., et al.
Publicado: (2022)

Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses
por: Konkolova, Eva, et al.
Publicado: (2020)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase
por: Byléhn, Fabian, et al.
Publicado: (2021)

Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex
por: Olotu, Fisayo A., et al.
Publicado: (2021)

Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
por: Stevens, Laura J., et al.
Publicado: (2022)

Phylogenetic Analysis of Guinea 2014 EBOV Ebolavirus Outbreak
por: Dudas, Gytis, et al.
Publicado: (2014)

Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro
por: Boccuto, Adele, et al.
Publicado: (2021)

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
por: Malespin, Miguel, et al.
Publicado: (2016)

IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study
por: Elfiky, Abdo A., et al.
Publicado: (2016)

Probing remdesivir nucleotide analogue insertion to SARS-CoV-2 RNA dependent RNA polymerase in viral replication
por: Romero, Moises E., et al.
Publicado: (2022)

Allosteric Activation of SARS-CoV-2 RNA-Dependent RNA Polymerase by Remdesivir Triphosphate and Other Phosphorylated Nucleotides
por: Wang, Bing, et al.
Publicado: (2021)

Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers—An MD Study
por: Bringas, Mauro, et al.
Publicado: (2022)

Repurposing FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, and remdesivir as potential inhibitors against RNA dependent RNA polymerase of SARS-CoV-2: A comparative in silico perspective
por: Shahabadi, Nahid, et al.
Publicado: (2023)

Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
por: Tchesnokov, Egor P., et al.
Publicado: (2020)

Translocation pause of remdesivir-containing primer/template RNA duplex within SARS-CoV-2’s RNA polymerase complexes
por: Shi, Yuanjun, et al.
Publicado: (2022)

Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation
por: Kato, Koichiro, et al.
Publicado: (2020)

Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report
por: Seifert, Leon Louis, et al.
Publicado: (2016)

Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico
por: Elfiky, Abdo A, et al.
Publicado: (2021)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i00hgh914lg4mbfvuiomv4kd2e